Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

by Bijay S Jaiswal, Vasantharajan Janakiraman, Noelyn M Kljavin, Jeffrey Eastham-Anderson, James E Cupp, Yuxin Liang, David P Davis, Klaus P Hoeflich, Somasekar Seshagiri
Published 2009-05-01

Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate

by Akhilesh Pandey, Eric W. Stawiski, Steffen Durinck, Harsha Gowda, Leonard D. Goldstein, Mustafa A. Barbhuiya, Markus S. Schröder, Sreelakshmi K. Sreenivasamurthy, Sun-Whe Kim, Sameer Phalke, Kushal Suryamohan, Kayla Lee, Papia Chakraborty, Vasumathi Kode, Xiaoshan Shi, Aditi Chatterjee, Keshava Datta, Aafaque A. Khan, Tejaswini Subbannayya, Jing Wang, Subhra Chaudhuri, Sanjiv Gupta, Braj Raj Shrivastav, Bijay S. Jaiswal, Satish S. Poojary, Shushruta Bhunia, Patricia Garcia, Carolina Bizama, Lorena Rosa, Wooil Kwon, Hongbeom Kim, Youngmin Han, Thakur Deen Yadav, Vedam L. Ramprasad, Amitabha Chaudhuri, Zora Modrusan, Juan Carlos Roa, Pramod Kumar Tiwari, Jin-Young Jang, Somasekar Seshagiri
Published 2020-08-01